Shattuck reports Q3 net loss $27.5M; SL-172154 PROC ORR ~27% vs 4% benchmark

Shattuck Labs, Inc.

2023-Q3 EPS reported -$1.64 revenue$943,000

Net loss of $27.5M ($0.65/share) for Q3 2023 vs $24.6M ($0.58/share) a year ago.
Cash and investments $101.1M as of Sep 30, 2023, sufficient to fund operations through 2024.
SL-172154 + PLD in PROC: 3 partial responses out of 11 evaluable patients (27% ORR), acceptable safety.
Topline data from Phase 1A/B in R/R AML/HR-MDS to be presented at ASH Dec 2023; abstract shows monotherapy response.
Expect to complete enrollment in PROC expansion and frontline HR-MDS cohorts in Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Shattuck Labs, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-23-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.